Your session is about to expire
← Back to Search
Other
Arm 1: Healthy Japanese Participants for Healthy Subjects
Phase 1
Waitlist Available
Research Sponsored by AbbVie
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 45 days
Awards & highlights
Summary
This trial will assess safety and how ABBV-552 moves through the body of 18 adult healthy Japanese & Han Chinese volunteers. Adverse Events will be monitored.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to approximately 45 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 45 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
AUC From Time Zero to Infinite Time (AUCinf) of ABBV-552
AUC of ABBV-552 (Arm 1)
Apparent Oral Clearance (CL/F) of ABBV-552
+8 moreTrial Design
2Treatment groups
Experimental Treatment
Group I: Arm 2: Healthy Han Chinese ParticipantsExperimental Treatment1 Intervention
Participants will receive ABBV-552 once a week for 7 Days.
Group II: Arm 1: Healthy Japanese ParticipantsExperimental Treatment1 Intervention
Participants will receive ABBV-552 once a week for 21 Days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ABBV-552
2023
Completed Phase 1
~30
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
AbbVieLead Sponsor
983 Previous Clinical Trials
509,343 Total Patients Enrolled
ABBVIE INC.Study DirectorAbbVie
414 Previous Clinical Trials
151,874 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger